F. Venturella, G. Cancellieri, M. Giammanco, A. Almerico, Igor Daniele Aleo, A. Liga, F. Mortillaro, Irene Mistretta
{"title":"Nivolumab对晚期非小细胞肺癌(NSCLC)的免疫肿瘤治疗","authors":"F. Venturella, G. Cancellieri, M. Giammanco, A. Almerico, Igor Daniele Aleo, A. Liga, F. Mortillaro, Irene Mistretta","doi":"10.4081/jbr.2023.11027","DOIUrl":null,"url":null,"abstract":"In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC), which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immuno-oncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells.","PeriodicalId":9116,"journal":{"name":"Bollettino della Societa italiana di biologia sperimentale","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab\",\"authors\":\"F. Venturella, G. Cancellieri, M. Giammanco, A. Almerico, Igor Daniele Aleo, A. Liga, F. Mortillaro, Irene Mistretta\",\"doi\":\"10.4081/jbr.2023.11027\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC), which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immuno-oncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells.\",\"PeriodicalId\":9116,\"journal\":{\"name\":\"Bollettino della Societa italiana di biologia sperimentale\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bollettino della Societa italiana di biologia sperimentale\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/jbr.2023.11027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bollettino della Societa italiana di biologia sperimentale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/jbr.2023.11027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Immuno-oncological treatment of Non-Small-Cell Lung Cancer (NSCLC) in advanced stage with Nivolumab
In recent years, significant scientific progress has been made in the therapy of non-small cell lung cancer (NSCLC), which has made possible a better knowledge of this pathology and above all the realization of new personalized therapies. The main therapeutic revolution in advanced NSCLC is immuno-oncology, a new therapeutic strategy that aims to awaken the immune system to fight cancer cells.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
